What are the latest advances in Alport Syndrome?

Until recently most doctors thought that Alport syndrome was an untreatable disease. However, experiments carried out in mice with Alport syndrome showed that several different kinds of medication could slow down loss of kidney function. Preliminary studies in people with Alport syndrome have also provided evidence that early treatment delays kidney failure. This means that Alport syndrome should be diagnosed early in childhood. It is very important for people with Alport syndrome to be examined regularly by a nephrologist so that effects of kidney disease, such as hypertension (high blood pressure), can be identified early and treated. Regular hearing and vision evaluation is also important. CARDINAL is a Phase 2/3 clinical study evaluating the safety and effectiveness of bardoxolone methyl (an oral investigational drug) for the treatment of Alport syndrome. Visit https://www.cardinalclinicaltrial.com/ to learn more.

2/6/18 by Reata Pharmaceuticals - CARDINAL Study for Alport Syndrome